Slide Source: Lipids Online Slide Library www.lipidsonline.org CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease: Recommendations.

Slides:

Advertisements

Similar presentations

EFFECTIVENESS OF PRIMARY CARE- RELEVANT TREATMENTS FOR OBESITY IN ADULTS: A SYSTEMATIC EVIDENCE REVIEW FOR THE U.S PREVENTIVE SERVICES LEBLANC ES, OCONNOR.

Advertisements

ADULT CARDIOLOGY IN PRIMARY CARE

Guidelines for the Primary Prevention of Stroke. A Guideline for Healthcare Professionals From the American Heart Association & American Stroke Association.

Consensus and Recommendations for LDL-P. Brunzell et al. Diabetes Care (4): “Measurement of LDL cholesterol (the cholesterol within.

NCEP ATP IV GuidelineS: 2013 Update

Leadership. Knowledge. Community. Introduction Canadian Cardiovascular Society Antiplatelet Guidelines.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Presenter Disclosure Information Diane Bild, MD, MPH Screening for Subclinical Atherosclerosis as a Strategy for CVD Prevention FINANCIAL DISCLOSURE: None.

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.

Diagnosis and Treatment of Dyslipidemia  New guidelines are based on the “Adult Treatment Plan III (ATP III)” 2004  Focus = multiple risk factor assessment.

1 Obesity Treatment in Special Populations Smokers –All smokers, regardless of weight, should quit smoking. –Implement weight gain prevention, treatment.

Slide Source: Lipids Online Slide Library Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients.

Slide Source: Lipids Online Plasma Concentration of TNF- and Risk of Recurrent Coronary Events –2.47 (1 st –50 th.

© 2002, Wellsource Inc. C-Reactive Protein A New Test for Cardiovascular Risk Prepared by Don Hall, DrPH Wellsource Inc.

{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.

RISK FACTOR FOR CORONARY ARTERY DISEASE

Estimate of Certainty (Precision) of Treatment Effect Level of evidence of B or C does not imply that recommendation is weak. LEVEL A Multiple populations.

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.

10 Points to Remember on the Assessment of Cardiovascular RiskAssessment of Cardiovascular Risk Summary Prepared by Melvyn Rubenfire, MD.

Myocardial Ischemia: Concepts in Management Topics in Clinical Medicine February 14, 2007.

Towards better screening of CV risk Paul Ridker MD Associate Professor of Medicine Division of Preventive Medicine and Cardiovascular Diseases Harvard.

Author: Moldovan Carmen Co-authors: Opincariu Diana Balan Daniel University of Medicine and Pharmacy Tg. Mures Cardiology Clinic, Mures Emergency Clinical.

Historical perspective It all started with Aspirin….

ACC/AHA 2006 guidelines on the management of PAD.

Slide Source: Lipids Online Slide Library LDL Cholesterol, mg/dL Years of Follow-up Ridker PM et al. N Engl J Med 2002;347:1557–1565.

Clinical Trial Results. org Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity.

BRIAN CLAYTON INTERNAL MEDICINE ADVISOR: ANNA MAE SMITH PRECEPTOR: DR. RAJESH PATEL Evidence Based Medicine Spring 2009.

Slide Source: Lipids Online Slide Library C-Reactive Protein, Metabolic Syndrome, and Risk for CV Events: Women’s Health Study 14,719.

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?

ACC/AHA Guidelines Not the Final or Only Word. Contemporary Guidelines

Slide Source: Lipids Online Slide Library Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Nissen SE et al. JAMA.

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2013 ACC/AHA Guideline on the Treatment of Blood.

Unnecessary Lipid Screening of Inpatient Admissions Dennis Whang 4/2/12 DSR2.

Presentation Title R3 이지영 / 김 수 중교 수 님. Introduction Lowering LDL cholesterol levels with statins : Reduce the risk of cardiovascular disease Vascular.

Findings suggest: Improvement was noted in both BMI and reported physical activity although the differences did not reach statistical difference. Behavior.

FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

The role of unknown risk factors in coronary heart disease

M.Sc. in Pharmacy/Clinical Laboratory Sciences

Copyright © 2017 American Academy of Pediatrics.

Cholesterol practice questions

BACKGROUND RESULTS OBJECTIVES METHODS CONCLUSIONS REFERENCES

CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

Classification of total cholesterol levels

Achieving the Clinical Potential of RAAS Blockade

AIM-HIGH Niacin Plus Statin to Prevent Vascular Events

FATS- Familial Atherosclerosis Treatment Study

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

The ASSERT Study.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Neil J. Stone et al. JACC 2014;63:

The following slides highlight a report on a presentation at the Canadian Cardiovascular Congress held in Toronto, Ontario from October 24 to 29, 2003.

Figure 3 Semantic model of the active surveillance (AS) timeline

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Clopidogrel Reduces ADP-Induced Expression of Platelet-derived CD40L

Personalizing Statin Therapy in Patients With HIV

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Rational Order of Laboratory Tests in Cardiovascular Diseases

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Figure 6 Combining population-wide and high-risk strategies

Contemporary Evidence-Based Guidelines

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Goals & Guidelines A summary of international guidelines for CHD

Glycated Hemoglobin Levels (A1C)

Cardiovascular Disease in Women Module III: Risk Assessment Tool

Cardiovascular Disease in Women Module IX: Presentation Resources and Internet Resources This slide set was updated April 2008.

The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Infliximab trough levels above 7 μg/mL in inflammatory bowel disease treated with infliximab: Better control of inflammation without increased risk of.

Presentation transcript:

Slide Source: Lipids Online Slide Library CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease: Recommendations for Population Science Class III (evidence/agreement that the procedure is not useful/effective and may be harmful), Evidence level C (consensus opinion of experts) The entire adult population should not be screened for hs-CRP for purposes of cardiovascular risk assessment Pearson TA et al. Circulation 2003;107:499–511.

Slide Source: Lipids Online Slide Library CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease: Recommendations for Laboratory Testing Class IIa (in favor of usefulness), Evidence level B (data derived from nonrandomized studies) 2 measurements, optimally 2 weeks apart, should be averaged, in fasting or nonfasting metabolically stable patients. If hs-CRP >10 mg/L, test should be repeated and patient examined for sources of infection or inflammation hs-CRP risk categories:  Low: <1 mg/L  Average: 1–3 mg/L  High: >3 mg/L Pearson TA et al. Circulation 2003;107:499–511.

Slide Source: Lipids Online Slide Library CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease: Recommendations for Clinical Practice (I) Class IIa (in favor of usefulness), Evidence level B (data derived from nonrandomized studies) In patients at intermediate global risk (10–20%/10 yr), hs-CRP measurement may help direct evaluation and therapy for primary prevention; benefits uncertain. Patients with persistent unexplained hs-CRP elevation >10 mg/L should be evaluated for noncardiovascular etiologies. In patients with stable coronary disease or ACS, hs- CRP may be useful as a marker of prognosis for recurrent events; benefits uncertain. Pearson TA et al. Circulation 2003;107:499–511.

Slide Source: Lipids Online Slide Library CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease: Recommendations for Clinical Practice (II) Class IIb (usefulness less well established), Evidence level B (data derived from nonrandomized studies) hs-CRP measurement may be used as part of global risk assessment in primary prevention; benefits uncertain. hs-CRP may improve motivation for lifestyle modification; benefits uncertain. Pearson TA et al. Circulation 2003;107:499–511.